A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Abstract Background Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. Methods We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient’s clinical status 30 days after the intervention, as measured on a six-point ordinal scale ranging from total recovery to death. Results A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200]. No patients were lost to follow-up. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83 (95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups. Conclusions No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535.)

[1]  T. Bhatnagar,et al.  Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.

[2]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[3]  J. Alcamí,et al.  Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial , 2020, medRxiv.

[4]  J. Mason,et al.  A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.

[5]  S. Zolla-Pazner,et al.  Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera , 2020, medRxiv.

[6]  A. Casadevall,et al.  Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience , 2020, medRxiv.

[7]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply. , 2020, The New England journal of medicine.

[8]  M. M. van der Eerden,et al.  Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.

[9]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[10]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[11]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[12]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[13]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[14]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[15]  P. Horby,et al.  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. , 2016, The New England journal of medicine.

[16]  P. Harris Research Electronic Data Capture (REDCap) - planning, collecting and managing data for clinical and translational research , 2012, BMC Bioinformatics.

[17]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Y. Guan,et al.  Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.

[19]  S. Hoffman,et al.  Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.

[20]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  J. Whitehead Sample size calculations for ordered categorical data. , 1993, Statistics in medicine.

[22]  J. Maiztegui,et al.  EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROME , 1979, The Lancet.

[23]  COVID-19 Convalescent Plasma EUA Decision Memo , 2020 .